|Articles|March 1, 2009

Pharmaceutical Executive

  • Pharmaceutical Executive-03-01-2009
  • Volume 0
  • Issue 0

Wishbone for Barrier Thearpeutic's Vusion

Author(s)Brittany Agro

It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference.

CRYING BABY

Wishbone

BRAND Vusion CLIENT Barrier Therapeutics FROM LEFT: Renee Mellas, partner, general manager; Scott Sager, senior vice president, creative director; Steve Hamburg, partner, chief creative officer

It's not unusual for creative teams to ask actors to work up on-screen tears. But when you go from crying actors to crying babies, it makes all the difference. That crying baby formed the basis of the print and television campaign Wishbone created for Barrier Therapeutics' anti-fungal pediatric ointment Vusion. "It's wired into parents as an incentive to action," says Steve Hamburg, partner/chief creative officer. "These are things that get parents' attention almost genetically."

The accompanying creative keeps consistent with the esthetic of "baby-ness." "It's time for a change" was used as a pun on the double meaning of the dirty diaper and the therapy.

Hamburg says that the DTC spot was so effective that it produced a dramatic increase in prescriptions for the drug.

Articles in this issue


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.